BrainsWay Q2 2026 revenue beats forecasts, shares rise

Medical device company BrainsWay Ltd. said on Wednesday its second-quarter 2026 revenue exceeded market forecasts, sending shares higher in after-hours trading.

The company, which develops and markets non-invasive brain stimulation systems, did not disclose specific revenue figures in its earnings call transcript. BrainsWay reported that revenue for the quarter surpassed consensus estimates provided by analysts, though it provided no further numerical details.

Executives emphasized continued growth in adoption of its Deep Transcranial Magnetic Stimulation (dTMS) systems for treating conditions such as depression and obsessive-compulsive disorder. The company highlighted expanding commercial partnerships and increasing clinical evidence supporting its technology as key drivers behind the revenue beat.

BrainsWay also reiterated its full-year 2026 guidance, stating it remains on track to meet previously issued targets. Management did not provide updated financial projections during the call.

Shares of BrainsWay, which trades on the Nasdaq under the ticker BWAY, climbed more than 5% in extended trading following the release of the earnings call transcript. The stock has gained roughly 15% year-to-date as of the close of regular trading on Wednesday.

Analysts had expected BrainsWay to report revenue of approximately $25 million for the quarter, according to consensus estimates compiled by Investing.com. The company’s prior quarter revenue totaled $23.7 million.

BrainsWay did not provide a breakdown of revenue by product line or geographic region in the transcript. Executives did note that international markets, particularly in Europe and Asia, continued to show steady demand for its dTMS systems.

The company’s next earnings release is scheduled for the third quarter of 2026.